1. IgG hexamers initiate complement-dependent acute lung injury.
- Author
-
Cleary SJ, Seo Y, Tian JJ, Kwaan N, Bulkley DP, Bentlage AE, Vidarsson G, Boilard É, Spirig R, Zimring JC, and Looney MR
- Subjects
- Animals, Mice, Humans, Complement Activation immunology, Mice, Transgenic, Isoantibodies immunology, Mutation, Missense, Disease Models, Animal, Amino Acid Substitution, Immunoglobulin Fc Fragments immunology, Immunoglobulin Fc Fragments genetics, Immunoglobulin Fc Fragments metabolism, Acute Lung Injury immunology, Acute Lung Injury pathology, Immunoglobulin G immunology, Receptors, IgG immunology, Receptors, IgG genetics, Receptors, IgG metabolism
- Abstract
Antibodies can initiate lung injury in a variety of disease states such as autoimmunity, in reactions to transfusions, or after organ transplantation, but the key factors determining in vivo pathogenicity of injury-inducing antibodies are unclear. Harmful antibodies often activate the complement cascade. A model for how IgG antibodies trigger complement activation involves interactions between IgG Fc domains driving the assembly of IgG hexamer structures that activate C1 complexes. The importance of IgG hexamers in initiating injury responses was not clear, so we tested their relevance in a mouse model of alloantibody- and complement-mediated acute lung injury. We used 3 approaches to block alloantibody hexamerization (antibody carbamylation, the K439E Fc mutation, or treatment with domain B from staphylococcal protein A), all of which reduced acute lung injury. Conversely, Fc mutations promoting spontaneous hexamerization made a harmful alloantibody into a more potent inducer of acute lung injury and rendered an innocuous alloantibody pathogenic. Treatment with a recombinant Fc hexamer "decoy" therapeutic protected mice from lung injury, including in a model with transgenic human FCGR2A expression that exacerbated pathology. These results indicate an in vivo role of IgG hexamerization in initiating acute lung injury and the potential for therapeutics that inhibit or mimic hexamerization to treat antibody-mediated diseases.
- Published
- 2024
- Full Text
- View/download PDF